Anheuser-Busch Inbev SA vs Illumina, Inc. — how do they compare? Anheuser-Busch Inbev SA trades at $79.97 (market cap $159.01B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Anheuser-Busch Inbev SA is far larger — about 5.5× Illumina, Inc.'s market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| BUD | ILMN | |
|---|---|---|
Market Cap | $159.01B | $29.12B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $205.10 |
52-Week Low | $57.93 | $91.00 |
Enterprise Value | $223.42B | $30.48B |
Dividend Yield | 1.67% | — |
Trailing returns across standard periods
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →